FORCE Act

House Bill

H.R. 3561

119th Congress

FORCE Act

In Committee

Introduced:May 21, 2025

Primary Sponsor

Joyce Beatty

Representative

Democratic

OH-3

Cosponsors

88

Quick Stats

Policy Area

Health

Summary

The PATIENT Act aims to make healthcare and prescription drug costs more transparent by expanding hospital price reporting requirements and mandating new disclosures from insurance companies and pharmacy benefit managers (PBMs). It also extends funding for certain healthcare programs.

Latest Action

Referred to the Subcommittee on Health.

SponsorJoyce Beatty (D-OH)

Introduced5/21/2025

StatusReferred to the House Committee on Financial Services.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

FORCE Act

The PATIENT Act aims to make healthcare and prescription drug costs more transparent by expanding hospital price reporting requirements and mandating new disclosures from insurance companies and pharmacy benefit managers (PBMs). It also extends funding for cer

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The PATIENT Act aims to make healthcare and prescription drug costs more transparent by expanding hospital price reporting requirements and mandating new disclosures from insurance companies and pharmacy benefit managers (PBMs). It also extends funding for certain healthcare programs.

Bill Number: 3561
Sponsor: Joyce Beatty (D-OH)
Introduced: 5/21/2025
Status: Referred to the House Committee on Financial Services.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: FORCE Act
Bill Number: 3561
Sponsor: Joyce Beatty (D-OH)
Status: Referred to the House Committee on Financial Services.
Introduced: 5/21/2025
Summary: The PATIENT Act aims to make healthcare and prescription drug costs more transparent by expanding hospital price reporting requirements and mandating new disclosures from insurance companies and pharmacy benefit managers (PBMs). It also extends funding for certain healthcare programs.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

The PATIENT Act aims to make healthcare and prescription drug costs more transparent by expanding hospital price reporting requirements and mandating new disclosures from insurance companies and pharmacy benefit managers (PBMs). It also extends funding for certain healthcare programs.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023 This bill expands hospital price transparency requirements and establishes additional reporting requirements with respect to prescription drugs and pharmacy benefit managers (PBMs). The bill also extends funding for various programs such as the Teaching Health Center Graduate Medical Education program, Community Health Center program, and National Health Service Corps. Specifically, the bill provides statutory authority for the requirement that hospitals publish an annual list of shoppable services they provide, including specified pricing information. Beginning in 2025, a hospital may not use an internet-based price estimator tool to meet the publication requirement for shoppable services. The bill also modifies the health insurance plan disclosure requirements to include the rates for certain in-network services and prescription drug payment information. The bill further requires providers of diagnostic laboratory tests under Medicare to publish online certain price information. Medicare Advantage (MA) organizations must report information about payments made to providers in which the MA organization has an ownership interest. Medicare prescription drug plan sponsors must report certain price information for covered drugs. Additionally, the bill requires health insurance plan issuers (or the PBM providing services on behalf of the plan) to report to the plan sponsor specified information about prescription drugs dispensed under the plan. This includes rebates, fees, alternative discounts, or other remuneration the plan receives from drug manufacturers. Finally, the bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid.

Key Points

Main provisions of the bill

Requires hospitals to publish annual lists of shoppable services with pricing details, and bans the use of online price estimator tools to meet this requirement by 2025.
Modifies insurance plan disclosure rules to include rates for certain in-network services and prescription drug payment information.
Requires Medicare providers, Medicare Advantage organizations, and Medicare prescription drug plan sponsors to report additional price information.

How This Impacts Americans

Potential effects on citizens and communities

If passed, this bill would impact patients, healthcare providers, insurance companies, and PBMs. Patients could potentially have more information to compare healthcare costs and make informed decisions. Providers and insurers would face new reporting requirements, while PBMs would be required to use pass-through pricing models for Medicaid. These changes aim to increase transparency and potentially lower healthcare and drug costs for consumers.

Policy Areas

Primary Policy Area

Health

Related Subjects

Accounting and auditing

Appropriations

Business records

Civil actions and liability

Community life and organization

Computers and information technology

Congressional oversight

Digestive and metabolic diseases

Freedom of information

Government information and archives

+9 more

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

3561, 119th Congress (2025). "FORCE Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3561

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.